Home
Heidelberg Pharma

Heidelberg Pharma Market Share Analysis for June 2026

heidelberg pharma ag ist ein biotechnologie-unternehmen, das antikörper-wirkstoff-konjugate für die krebstherapie entwickelt.

Health > Biotechnology and Pharmaceuticals

Domainheidelberg-pharma.com

Year Founded1997

Employees51 - 200

Annual Revenue$2M - $5M

Heidelberg Pharma

Heidelberg Pharma (including company regionals)

heidelberg-pharma.com

See more website traffic and engagement information

Heidelberg Pharma Revenue up to June 2026 is 2M - 5M

revenue generated by Heidelberg Pharma top domains

Heidelberg Pharma top domains revenue over 3 years

Revenue for Heidelberg Pharma top domains

heidelberg-pharma.com2M - 5M

See more with Sales Intelligence

Total visits to Heidelberg Pharma's top domains

Understand Heidelberg Pharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

heidelberg-pharma.com2.2K

See more with Sales Intelligence

Avg. visit duration in Heidelberg Pharma's top domains

Analyze Heidelberg Pharma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

heidelberg-pharma.com00:00:21

See more with Sales Intelligence

Avg. pageviews on Heidelberg Pharma's top domains

See how Heidelberg Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

heidelberg-pharma.com1.67

See more with Sales Intelligence

Heidelberg Pharma top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Heidelberg Pharma

These are the website technologies, by industry, used by Heidelberg Pharma top domains

Advertising (2)

PubMatic

Content Management System (2)

WordPress

Conversion & Analytics (2)

Google Analytics

Mobile (2)

Meta Viewport

More Technologies

5

See all

News & Signals from Heidelberg Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAndreas Pahl left Heidelberg Pharma AG as chief executive on Jul 15th '26.Swedish biologics company Simris Group (Nasdaq First North Growth Market: SIMRIS) has appointed former Heidelberg Pharma chief executive Andreas Pahl (pictured above) to lead its German subsidiary, Simris Biologics, as it works to advance its antibody-drug conjugate (ADC) payload platform.

NewsHeidelberg Pharma AG hired Jack Yefei Ling as Supervisory Board on Jun 23rd '26.Heidelberg Pharma shareholders approve all agenda items at 2026 Annual General Meeting, elect Jack Yefei Ling to Supervisory Board.

NewsHeidelberg Pharma AG launched ADC technology platform at AACR annual meeting on Jan 1st '26.EQS news: heidelberg pharma presents results of its proprietary ADC technology platform at the AACR annual meeting 2026.